The Joint Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for The Joint in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" The Joint stock.
View analyst ratings for The Joint or view top-rated stocks.

Wall Street analysts have given The Joint a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but The Joint wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

The Joint Corp. (NASDAQ:JYNT) released its quarterly earnings data on Wednesday, March, 3rd. The company reported $0.72 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.14 by $0.58. The Joint had a net margin of 6.89% and a trailing twelve-month return on equity of 51.77%.
View The Joint's earnings history.

The Joint's stock was trading at $13.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, JYNT shares have increased by 227.2% and is now trading at $44.53.
View which stocks have been most impacted by COVID-19.

The Joint issued an update on its FY 2021 After-Hours earnings guidance on Thursday, March, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $73-77 million, compared to the consensus revenue estimate of $72.23 million.

5 brokers have issued twelve-month price objectives for The Joint's stock. Their forecasts range from $35.00 to $54.00. On average, they expect The Joint's stock price to reach $45.60 in the next year. This suggests a possible upside of 2.4% from the stock's current price.
View analysts' price targets for The Joint or view top-rated stocks among Wall Street analysts.

87 employees have rated The Joint CEO Peter D. Holt on Glassdoor.com. Peter D. Holt has an approval rating of 59% among The Joint's employees. This puts Peter D. Holt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to The Joint include Marathon Patent Group (MARA), InterDigital (IDCC), Franchise Group (FRG), Liberty Tax (TAXA), VirnetX (VHC), Acacia Research (ACTG), Quarterhill (QTRHF), Pendrell (PCOA), Research Frontiers (REFR), Network-1 Technologies (NTIP), MGT Capital Investments (MGTI), Xcel Brands (XELB), Health Discovery (HDVY), Mills Music Trust (MMTRS) and Micro Imaging Technology (MMTC).
View all of JYNT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other The Joint investors own include Aurora Cannabis (ACB), Advanced Micro Devices (AMD), Raytheon Technologies (RTX), salesforce.com (CRM), Mastercard (MA), Starbucks (SBUX), Twitter (TWTR), Viking Therapeutics (VKTX), AbbVie (ABBV) and Adobe (ADBE).

(JYNT) raised $20 million in an initial public offering (IPO) on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager.

The Joint trades on the NASDAQ under the ticker symbol "JYNT."

The Joint's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.14%), Next Century Growth Investors LLC (4.82%), THB Asset Management (2.00%), Royce & Associates LP (1.59%), Morgan Stanley (1.52%) and Northern Trust Corp (1.37%). Company insiders that own The Joint stock include Bandera Partners Llc, Glenn J Krevlin, Jake Singleton, James H Amos Jr, Peter D Holt and Ronald V Davella.
View institutional ownership trends for The Joint.

JYNT stock was sold by a variety of institutional investors in the last quarter, including HighTower Advisors LLC, Old Well Partners LLC, Next Century Growth Investors LLC, THB Asset Management, Select Equity Group L.P., Northern Trust Corp, Hsbc Holdings PLC, and STA Wealth Management LLC.
View insider buying and selling activity for The Joint or view top insider-selling stocks.

JYNT stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Acuitas Investments LLC, Renaissance Technologies LLC, BlackRock Inc., Ingalls & Snyder LLC, Wells Fargo & Company MN, JPMorgan Chase & Co., and Engineers Gate Manager LP. Company insiders that have bought The Joint stock in the last two years include Bandera Partners Llc, Jake Singleton, James H Amos Jr, and Peter D Holt.
View insider buying and selling activity for The Joint or or view top insider-buying stocks.

Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of JYNT stock can currently be purchased for approximately $44.53.

The Joint has a market capitalization of $625.25 million and generates $48.45 million in revenue each year. The company earns $3.32 million in net income (profit) each year or $0.23 on an earnings per share basis.

The Joint employs 150 workers across the globe.

The official website for The Joint is www.thejoint.com.

The Joint is headquartered at 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260.

The Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-245-5960 or via email at [email protected]